A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019.
10.1097/CM9.0000000000001614
- Author:
Fengqin ZHANG
1
;
Yanqiu WEI
2
;
Li HE
3
;
Huilan ZHANG
1
;
Qiongjie HU
4
;
Huihui YUE
1
;
Jianhan HE
1
;
Huaping DAI
5
Author Information
1. Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
2. Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 10029, China.
3. Department of Respiratory and Critical Care Medicine, Jingzhou Central Hospital, Jingzhou, Hubei 434200, China.
4. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
5. Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use*;
COVID-19/drug therapy*;
Humans;
Pyridones/therapeutic use*;
Treatment Outcome
- From:Chinese Medical Journal
2021;135(3):368-370
- CountryChina
- Language:English